Oncopeptides Ab (publ) Stock Earnings Reports

Oncopeptides delivered a strategically important Q3 2025 with continued commercial momentum across Europe and stronger financial footing following an oversubscribed rights issue. Net sales were SEK 20.2 million (up 174% YoY), marking the fourth consecutive quarter-over-quarter growth and all-time monthly highs in July and September despite typical European vacation-season softness. Gross margin was exceptional at 99% and gross profit SEK 19.9 million. Operating expenses declined slightly (~3%) and EBIT improved versus prior year (from -SEK 61.3m to -SEK 47.1m for the quarter). Cash after the rights issue was SEK 147.9 million, providing runway toward the company’s goal of becoming cash flow positive by end of 2026, assuming continued sales growth. Commercially, Pepaxti is gaining scientific recognition (inclusion in EHA/EMN guidelines, real-world data presentations) and broader market access across key European markets (Italy, Spain, Germany), with >550 patients treated since launch. Management is advancing partnership discussions for Japan (late-stage due diligence) and has existing partnerships in South Korea and other regions. The company continues preclinical advancement of its PDC platform and a next-generation NK-cell engager (SPiKEs) program, while prioritizing cost discipline and investigator-initiated studies to close evidence gaps. Key risks/near-term milestones: securing a Japan partner, continued monthly/quarterly sales momentum (seasonality remains), and timing/financing for advancing SPiKEs to clinic.